ImmuniQ

Company Overview

Snapshot

Founded in January 2022 by Moshe Elkabets and Angel Porgador, ImmuniQ operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing its core technology.

Business overview

ImmuniQ is a Health Tech & Life Sciences company focused on personalized immuno-oncology treatment. The company has developed a method for quantifying the actual and functional tumor response to immunotherapy drugs. Its core technology, immune checkpoint artificial reporter (IcAR), quantifies binding and shows the actual surface activity of a patient’s cancer cells, aiming to enable more effective treatment. ImmuniQ serves the pharmaceuticals and cancer treatment markets within the life sciences sector.

Company Intelligence Q&A

When was ImmuniQ founded?

ImmuniQ was founded in January 2022.

Who are the founders of ImmuniQ?

ImmuniQ was co-founded by Moshe Elkabets and Angel Porgador.

What is ImmuniQ's primary focus?

ImmuniQ focuses on personalized immuno-oncology treatment, developing methods to quantify tumor response to immunotherapy drugs.

What is ImmuniQ's core technology?

ImmuniQ's core technology is the immune checkpoint artificial reporter (IcAR), which quantifies binding and surface activity of cancer cells to guide treatment.

What is the current employee size of ImmuniQ?

ImmuniQ currently has 1–10 employees.